Decipher Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer, STAMPEDE Data Show
VCYT sits 55% above its 52-week low of $29.455.
Summary
New STAMPEDE analysis gives Decipher its first Level 1B predictive evidence in very high-risk nonmetastatic prostate cancer: the treatment-by-test interaction for distant metastasis was significant (p=0.01) in node-negative patients. At five years, adding abiraterone cut distant metastasis events by 10% in high-score patients and 11% in very-high-score patients, versus 2% for low scores. That is a concrete clinical reason to order the test before treatment intensification, not just a prognostic one. It follows the September 29 NRG/RTOG 0815 readout and the NCCN 2027 guideline inclusion, building a widening evidence base for Decipher across the risk continuum. The data are retrospective and come from a 401-patient cohort, so they support reimbursement and adoption arguments rather than changing near-term numbers. The phase III PREDICT-RT (NRG-GU009) trial, which finished enrollment this year, will provide prospective validation.
At the time of this announcement, VCYT was trading at $45.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $29.46 to $60.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.